Matches in SemOpenAlex for { <https://semopenalex.org/work/W3021518560> ?p ?o ?g. }
- W3021518560 endingPage "414" @default.
- W3021518560 startingPage "414" @default.
- W3021518560 abstract "Traumatic brain injury (TBI) often causes massive brain cell death accompanied by the accumulation of toxic factors in interstitial and cerebrospinal fluids. The persistence of the damaged brain area is not transient and may occur within days and weeks. Chaperone Hsp70 is known for its cytoprotective and antiapoptotic activity, and thus, a therapeutic approach based on chemically induced Hsp70 expression may become a promising approach to lower post-traumatic complications. To simulate the processes of secondary damage, we used an animal model of TBI and a cell model based on the cultivation of target cells in the presence of cerebrospinal fluid (CSF) from injured rats. Here we present a novel low molecular weight substance, PQ-29, which induces the synthesis of Hsp70 and empowers the resistance of rat C6 glioma cells to the cytotoxic effect of rat cerebrospinal fluid taken from rats subjected to TBI. In an animal model of TBI, PQ-29 elevated the Hsp70 level in brain cells and significantly slowed the process of the apoptosis in acceptor cells in response to cerebrospinal fluid action. The compound was also shown to rescue the motor function of traumatized rats, thus proving its potential application in rehabilitation therapy after TBI." @default.
- W3021518560 created "2020-05-13" @default.
- W3021518560 creator A5001141720 @default.
- W3021518560 creator A5009729836 @default.
- W3021518560 creator A5019631216 @default.
- W3021518560 creator A5024204774 @default.
- W3021518560 creator A5039428258 @default.
- W3021518560 creator A5061310616 @default.
- W3021518560 creator A5068500099 @default.
- W3021518560 creator A5077732515 @default.
- W3021518560 creator A5081876600 @default.
- W3021518560 creator A5086800999 @default.
- W3021518560 creator A5090053515 @default.
- W3021518560 creator A5090980269 @default.
- W3021518560 date "2020-04-30" @default.
- W3021518560 modified "2023-10-15" @default.
- W3021518560 title "Pyrrolylquinoxaline-2-One Derivative as a Potent Therapeutic Factor for Brain Trauma Rehabilitation" @default.
- W3021518560 cites W137337681 @default.
- W3021518560 cites W147769263 @default.
- W3021518560 cites W1635149498 @default.
- W3021518560 cites W1931074504 @default.
- W3021518560 cites W1983621019 @default.
- W3021518560 cites W1983838222 @default.
- W3021518560 cites W1984431577 @default.
- W3021518560 cites W1994650544 @default.
- W3021518560 cites W1995289028 @default.
- W3021518560 cites W1995504152 @default.
- W3021518560 cites W2014311428 @default.
- W3021518560 cites W2018460125 @default.
- W3021518560 cites W2021233583 @default.
- W3021518560 cites W2055607326 @default.
- W3021518560 cites W2062819972 @default.
- W3021518560 cites W2074637456 @default.
- W3021518560 cites W2085393337 @default.
- W3021518560 cites W2089061310 @default.
- W3021518560 cites W2091742953 @default.
- W3021518560 cites W2111389066 @default.
- W3021518560 cites W2131631598 @default.
- W3021518560 cites W2140197221 @default.
- W3021518560 cites W2174411482 @default.
- W3021518560 cites W2214568589 @default.
- W3021518560 cites W2219854021 @default.
- W3021518560 cites W2332064688 @default.
- W3021518560 cites W2482458277 @default.
- W3021518560 cites W2515200327 @default.
- W3021518560 cites W2579265858 @default.
- W3021518560 cites W2579917909 @default.
- W3021518560 cites W2582898318 @default.
- W3021518560 cites W2615742554 @default.
- W3021518560 cites W2624703230 @default.
- W3021518560 cites W2763743717 @default.
- W3021518560 cites W2769633558 @default.
- W3021518560 cites W2773138292 @default.
- W3021518560 cites W2800143701 @default.
- W3021518560 cites W2804483360 @default.
- W3021518560 cites W2887637080 @default.
- W3021518560 cites W2891636448 @default.
- W3021518560 cites W2895939677 @default.
- W3021518560 cites W2964841380 @default.
- W3021518560 cites W2990737501 @default.
- W3021518560 cites W2991096547 @default.
- W3021518560 cites W2999803610 @default.
- W3021518560 cites W3005784714 @default.
- W3021518560 cites W566748824 @default.
- W3021518560 doi "https://doi.org/10.3390/pharmaceutics12050414" @default.
- W3021518560 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7285016" @default.
- W3021518560 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32366047" @default.
- W3021518560 hasPublicationYear "2020" @default.
- W3021518560 type Work @default.
- W3021518560 sameAs 3021518560 @default.
- W3021518560 citedByCount "2" @default.
- W3021518560 countsByYear W30215185602021 @default.
- W3021518560 countsByYear W30215185602022 @default.
- W3021518560 crossrefType "journal-article" @default.
- W3021518560 hasAuthorship W3021518560A5001141720 @default.
- W3021518560 hasAuthorship W3021518560A5009729836 @default.
- W3021518560 hasAuthorship W3021518560A5019631216 @default.
- W3021518560 hasAuthorship W3021518560A5024204774 @default.
- W3021518560 hasAuthorship W3021518560A5039428258 @default.
- W3021518560 hasAuthorship W3021518560A5061310616 @default.
- W3021518560 hasAuthorship W3021518560A5068500099 @default.
- W3021518560 hasAuthorship W3021518560A5077732515 @default.
- W3021518560 hasAuthorship W3021518560A5081876600 @default.
- W3021518560 hasAuthorship W3021518560A5086800999 @default.
- W3021518560 hasAuthorship W3021518560A5090053515 @default.
- W3021518560 hasAuthorship W3021518560A5090980269 @default.
- W3021518560 hasBestOaLocation W30215185601 @default.
- W3021518560 hasConcept C102652120 @default.
- W3021518560 hasConcept C104317684 @default.
- W3021518560 hasConcept C118552586 @default.
- W3021518560 hasConcept C142724271 @default.
- W3021518560 hasConcept C154317977 @default.
- W3021518560 hasConcept C185592680 @default.
- W3021518560 hasConcept C190283241 @default.
- W3021518560 hasConcept C202751555 @default.
- W3021518560 hasConcept C205260736 @default.
- W3021518560 hasConcept C2779651940 @default.
- W3021518560 hasConcept C2781017439 @default.